•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Johnson & Johnson Q3 Earnings Preview: Dividend Dependability And Steady Growth
Retirees: Focus on Dividend Growth With These 3 Stocks
What Trends Will Drive Johnson & Johnson's Q3 Results?
What You Need to Know Ahead of Johnson & Johnson's Earnings
J&J talc bankruptcy stays in Texas despite 'forum-shopping" opposition
Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference
Johnson & Johnson: You Need To Look At This Chart (Rating Upgrade)
Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis
Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab) SC-based quadruplet regimen for newly diagnosed multiple myeloma patients
Buy 4 October Dividend Aristocrats & Watch 10
Johnson & Johnson (JNJ) Completes Acquisition of V-Wave Ltd for $600 Million
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Should Investors Consider High Yield Dividend Stocks?
What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week?
Analysts Estimate Johnson & Johnson (JNJ) to Report a Decline in Earnings: What to Look Out for
Undervalued Dividend Kings: October 2024
Johnson & Johnson (JNJ) Halts TAR-200 Bladder Cancer Trial, Future FDA Plans Remain
J&J discontinues late-stage study for bladder cancer drug
Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.